Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel.

Armelle DufresneValéry AttignonAnthony FerrariLaurie TononSandrine BoyaultSéverine Tabone-EglingerPhilippe CassierOlivier TrédanNadège CorradiniArmelle VinceneuxAurélie SwalduzAlain ViariSylvie ChabaudDavid PérolJean Yves BlayPierre Saintigny

Published in: Cancer medicine (2024)

In advanced and refractory cancer patients in whom no MBTR was recommended from TGP/aCGH, WES/RNA-Seq allowed to identify more alterations which may in turn, in a limited fraction of patients, lead to new MBTR.

Keyphrases

rna seq
single cell
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
copy number
prognostic factors
squamous cell carcinoma
genome wide
gene expression
young adults
squamous cell